A Comparison of 3 Tumor Markers (MIA, TA90IC, S100B) in Stage III Melanoma Patients

REFERENCES

• Balch C., Buzaid A., Soong S., Atkins M., Cascinelli N., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 2001; 19: 3635–3648
   PubMed Web of Science ®Google Scholar
• Hsueh E., Essner R., Foshag L., Ollila D., Gammon G., O'Day S., Boasberg P., Stern S., Ye X., Morton D. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J. Clin. Oncol. 2002; 20: 4549–4554
   PubMed Web of Science ®Google Scholar
• Balch C., Soong S., Atkins M., Buzaid A., Cascinelli N., et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J. Clin. 2004; 54: 131–149
   PubMed Web of Science ®Google Scholar
• Rebmann V., Ugurel S., Tilgen W., Reinhold U., Grosse-Wilde H. Souble HLA-DR is a potent predicitive indicator of disease progression in serum from early-stage melanoma patients. Int. J. Cancer 2002; 100: 580–585
   PubMed Web of Science ®Google Scholar
• Banfalvi T., Gilde K., Boldizsar M., Kremmer T. Clinical significance of 5-S-cysteinyldopa monitoring in patients with malignant melanoma. Neoplasma. 2002; 49: 121–125
   PubMed Web of Science ®Google Scholar
• Gogas H., Kefala G., Bafaloukos D., Frangia K., Polyzos A., et al. Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon. Br. J. Cancer 2002; 87: 181–186
   PubMed Web of Science ®Google Scholar
• Wakamatsu K., Kageshita T., Furue M., Hatta N., Kiyohara Y., et al. Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience. Melanoma Res. 2002; 12: 245–253
   PubMed Web of Science ®Google Scholar
• Stoitchkov K., Letellier S., Garnier J., Bousquet B., Tsankov N., et al. Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B. Melanoma Res. 2002; 12: 255–262
   PubMed Web of Science ®Google Scholar
• Vuoristo M., Kellokumpu-Lehtinen P., Laine S., Parvinen L., Hahka-Kemppinen M., et al. The value of serum S-100B and interleukins as tumour markers in advanced melanoma. Melanoma Res. 2000; 10: 237–241
   PubMed Web of Science ®Google Scholar
• Dutcher J. The prognostic role of detecting circulating melanoma cells in the blood. J. Clin. Oncol. 2003; 21: 757–759
   PubMed Web of Science ®Google Scholar
• Wascher R., Morton D., Kuo C., Elashoff R., Wang H., et al. Molecular tumor markers in the blood: Early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. J. Clin. Oncol. 2003; 21: 2558–2563
   PubMed Web of Science ®Google Scholar
• Gupta R., Morton D. Monoclonal antibody-based ELISA to detect glycoprotein tumor-associated-antigen-specific immune complexes in cancer. J. Clin. Lab. Analysis. 1992; 6: 329–336
   PubMed Web of Science ®Google Scholar
• Gupta R., Morton D. Immunochemical characterization of fetal antigen isolated from spent medium of a human melanoma cell line. J. Natl. Cancer Inst. 1983; 70: 993
   PubMed Web of Science ®Google Scholar
• Hsueh E., Gupta R., Qi K., Yee R., Leopoldo Z., et al. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma. Cancer J. Sci. Am. 1997; 3: 364–370
   PubMed Web of Science ®Google Scholar
• Euhus D., Gupta R., Morton D. Characterization of a 90–100 kDa Tumor-associated antigen in the sera of melanoma patients. Int. J. Cancer. 1990; 45: 1065–1070
   PubMed Web of Science ®Google Scholar
• Tsioulias G., Gupta R., Tisman G., Hsueh E., Essner R., et al. Serum TA90 antigen-antibody complex as a surrogate marker of the efficacy of a polyvalent allogeneic whole-cell vaccine (CancerVax) in melanoma. Ann. Surg. Oncol. 2001; 8: 198–203
   PubMed Web of Science ®Google Scholar
• Bosserhoff A., Kaufmann M., Kaluza B., Bartke I., Zirngibl H., et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res. 1997; 57: 3149–3153
   PubMed Web of Science ®Google Scholar
• Guba M., Bosserhoff A., Steinbauer M., Abels C., Anthuber M., et al. Overexpression of melanoma inhibitory activity (MIA) enhances extravasation and metastasis of A-mel3 melanoma cells in vivo. Br. J. Cancer. 2000; 83: 1216–1222
   PubMed Web of Science ®Google Scholar
• Bosserhoff A., Buettner R. Expression, function and clinical relevance of MIA (melanoma inhibitory activity.). Histol Histopathol. 2002; 17: 289–300
   PubMed Web of Science ®Google Scholar
• Meral R., Duranyildiz D., Tas F., Camlica H., Yasasever V., et al. Prognostic significance of melanoma inhibiting activity levels in malignant melanoma. Melanoma Res. 2001; 11: 627–632
   PubMed Web of Science ®Google Scholar
• Dreau D., Bosserhoff A., White R., Buettner R., Holder W. Melanoma-inhibiting activity protein concentrations in blood of melanoma patients treated with immunotherapy. Oncol. Res. 1999; 11: 55–61
   PubMed Web of Science ®Google Scholar
• Faries M., Gupta R., Ye X., Hsueh E., Morton D. Melanoma-inhibiting activity assay predicts survival in patients receiving a therapeutic cancer vaccine after complete resection of American Joint Committee on Cancer Stage III melanoma. Ann. Surg. Oncol. 2004; 11: 85–93
   PubMed Web of Science ®Google Scholar
• Cochran A., Lu H., Li P., Saxton R., Wen D. S-100 protein remains a practical marker for melanocytic and other tumours. Melanoma Res. 1993; 3: 325–330
   PubMed Web of Science ®Google Scholar
• Acland K., Evans A., Abraha H., Healy C., Roblin P., et al. Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma. Br. J. Dermatol. 2002; 146: 832–835
   PubMed Web of Science ®Google Scholar
• Reinhardt M., Kensy J., Frohmann J., Willkomm P., Reinhold U., et al. Value of tumor marker S-100B in melanoma patients: a comparison to 18F-FDG PET and clinical data. Nuklearmedizin. 2002; 41: 143–147
   PubMedGoogle Scholar
• Deichmann M., Benner A., Bock M., Jackel A., Uhl K., et al. S100-beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J. Clin. Oncol. 1999; 17: 1891–1896
   PubMed Web of Science ®Google Scholar
• Djukanovic D., Hofmann U., Sucker A., Rittgen W., Schadendorf D. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Anticancer Res. 2000; 20: 2203–2207
   PubMed Web of Science ®Google Scholar
• Juergensen A., Holzapfel U., Hein R., Stolz W., Buettner R., et al. Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta. Tumour Biol. 2001; 22: 54–58
   PubMed Web of Science ®Google Scholar
• Krahn G., Kaskel P., Sander S., Waizenhofer P., Wortmann S., et al. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastasis compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res. 2001; 21: 1311–1316
   PubMed Web of Science ®Google Scholar
• Schmitz C., Brenner W., Henze E., Christophers E., Hauschild A. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients. Anticancer Res. 2000; 20: 5059–5063
   PubMed Web of Science ®Google Scholar
• Garbe C., Leiter U., Ellwanger U., Blaheta H., Meier F., et al. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibiting activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer. 2003; 97: 1737–1745
   PubMed Web of Science ®Google Scholar
• Gupta R., Theofilopoulos A., Dixon F., Morton D. Circulating immune complexes as possible cause for anticomplementary activity in humans with malignant melanoma. Cancer Immunol. Immunother. 1979; 6: 211–221
   Web of Science ®Google Scholar
• Hoon D., Bostick P., Kuo C., Okamoto T., Wang H., et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 2000; 60: 2253–2257
   PubMed Web of Science ®Google Scholar
• Dunn G., Bruce A., Ikeda H., Old L., Schreiber R. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002; 3: 991–998
   PubMed Web of Science ®Google Scholar
• Mackie R., Reid R., Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N. Engl. J. Med. 2003; 34: 567–568
   Google Scholar